MRNA is the author’s largest individual holding at ~19% after a massive gain; he explicitly says he still believes in the company long-term. Keeping the bulk of the position after taking profits signals ongoing conviction and a long-term bullish view. Existing MRNA holders may stay long, but this is not a fresh entry thesis with valuation support. Vaccine demand shifts, regulatory/clinical setbacks, and extreme concentration could reverse gains quickly.
MRNA is the author’s largest individual holding at ~19% after a massive gain; he explicitly says he still believes in the company long-term. Keeping the bulk of the position after taking profits signals ongoing conviction and a long-term bullish view. Existing MRNA holders may stay long, but this is not a fresh entry thesis with valuation support. Vaccine demand shifts, regulatory/clinical setbacks, and extreme concentration could reverse gains quickly.